Inclusion Criteria
Patients must have:
- Asymptomatic HIV infection.
- CD4 count 100-400 cells/mm3.
- No HIV-associated neurologic abnormalities or constitutional symptoms.
- No oral hairy leukoplakia.
- At least 6 months of prior AZT.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Abnormal chest x-ray, consistent with active opportunistic infection.
- Hypersensitivity to thymopentin.
- Significant chronic underlying medical illness.
- Grade 2 or worse peripheral neuropathy.
Concurrent Medication:
Excluded:
- HIV vaccines.
- Investigational or non-FDA approved medication.
- Immunomodulatory therapies.
- Experimental therapies.
- Any antiretroviral therapy other than AZT, ddI, ddC, d4T, or 3TC.
Patients with the following prior conditions are excluded:
- Herpes zoster (within the past year).
- Recurrent (> one episode) oral candidiasis (confirmed).
- Vulvovaginal candidiasis (persistent, frequent, or poorly responsive to therapy).
- Bacillary angiomatosis.
- Listeriosis.
- Idiopathic thrombocytopenia purpura.
Prior Medication:
Excluded at any time prior to study entry:
More than one dose of thymopentin.
Excluded within 30 days prior to study entry:
- HIV vaccines.
- Investigational or non-FDA approved medication.
- Immunomodulatory therapies.
- Experimental therapies.
- Any antiretroviral therapy other than AZT, ddI, ddC, d4T, or 3TC.
Required:
- Prior AZT (>= 300 mg/day) for at least 6 months; on current regimen (any combination of approved nucleoside analogues) for at least 4 weeks.
Significant active alcohol or drug abuse.
Purpose
